<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation - Salazar, CA - 2014 | Cochrane Library</title> <meta content="Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation - Salazar, CA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009893.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation - Salazar, CA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009893.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009893.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation" name="citation_title"/> <meta content="Carlos A Salazar" name="citation_author"/> <meta content="Universidad Peruana Cayetano Heredia" name="citation_author_institution"/> <meta content="caso90@gmail.com" name="citation_author_email"/> <meta content="Daniel del Aguila" name="citation_author"/> <meta content="Universidad Peruana Cayetano Heredia" name="citation_author_institution"/> <meta content="Erika G Cordova" name="citation_author"/> <meta content="Universidad Peruana Cayetano Heredia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD009893.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/03/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009893.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009893.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009893.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amidines [therapeutic use]; Antithrombins [adverse effects, *therapeutic use]; Atrial Fibrillation [*complications]; Azetidines [adverse effects, therapeutic use]; Benzimidazoles [therapeutic use]; Benzylamines [adverse effects, therapeutic use]; Dabigatran; Drug Administration Schedule; Embolism [etiology, *prevention &amp; control]; Randomized Controlled Trials as Topic; Safety‐Based Drug Withdrawals; Stroke [etiology, *prevention &amp; control]; Vitamin K [*antagonists &amp; inhibitors]; Warfarin [therapeutic use]; beta‐Alanine [analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009893.pub2&amp;doi=10.1002/14651858.CD009893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009893\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009893\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ko","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009893.pub2",title:"Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non\\u2010valvular atrial fibrillation",firstPublishedDate:"Mar 27, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009893.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009893.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009893.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009893.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009893.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009893.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009893.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009893.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009893.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009893.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4270 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009893.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0036"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/appendices#CD009893-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/table_n/CD009893StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/table_n/CD009893StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#CD009893-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Carlos A Salazar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#CD009893-cr-0003">Daniel del Aguila</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information#CD009893-cr-0004">Erika G Cordova</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information/en#CD009893-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 March 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009893.pub2">https://doi.org/10.1002/14651858.CD009893.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009893-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009893-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009893-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009893-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009893-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009893-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009893-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009893-abs-0001" lang="en"> <section id="CD009893-sec-0001"> <h3 class="title" id="CD009893-sec-0001">Background</h3> <p>Chronic anticoagulation with vitamin K antagonists (VKAs) prevents ischaemic stroke and systemic embolism in people with non‐valvular atrial fibrillation (AF) but dose adjustment, coagulation monitoring and bleeding limits its use. Direct thrombin inhibitors (DTIs) are under investigation as potential alternatives. </p> </section> <section id="CD009893-sec-0002"> <h3 class="title" id="CD009893-sec-0002">Objectives</h3> <p>To assess (1) the comparative efficacy of long‐term anticoagulation using DTIs versus VKAs on vascular deaths and ischaemic events in people with non‐valvular AF, and (2) the comparative safety of chronic anticoagulation using DTIs versus VKAs on (a) fatal and non‐fatal major bleeding events including haemorrhagic strokes, (b) adverse events other than bleeding and ischaemic events that lead to treatment discontinuation and (c) all‐cause mortality in people with non‐valvular AF. </p> </section> <section id="CD009893-sec-0003"> <h3 class="title" id="CD009893-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (July 2013), the Cochrane Central Register of Controlled Trials (CENTRAL), (<i>The Cochrane Library</i>, May 2013), MEDLINE (1950 to July 2013), EMBASE (1980 to October 2013), LILACS (1982 to October 2013) and trials registers (September 2013). We also searched the websites of clinical trials and pharmaceutical companies and handsearched the reference lists of articles and conference proceedings. </p> </section> <section id="CD009893-sec-0004"> <h3 class="title" id="CD009893-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing DTIs versus VKAs for prevention of stroke and systemic embolism in people with non‐valvular AF. </p> </section> <section id="CD009893-sec-0005"> <h3 class="title" id="CD009893-sec-0005">Data collection and analysis</h3> <p>All three review authors independently performed data extraction and assessment of risk of bias. Primary analyses compared all DTIs combined versus warfarin. We performed post hoc analyses excluding ximelagatran because this drug was withdrawn from the market owing to safety concerns. </p> </section> <section id="CD009893-sec-0006"> <h3 class="title" id="CD009893-sec-0006">Main results</h3> <p>We included eight studies involving a total of 27,557 participants with non‐valvular AF and one or more risk factors for stroke; 26,601 of them were assigned to standard doses groups and included in the primary analysis. The DTIs: dabigatran 110 mg twice daily and 150 mg twice daily (three studies, 12,355 participants), AZD0837 300 mg once per day (two studies, 233 participants) and ximelagatran 36 mg twice per day (three studies, 3726 participants) were compared with the VKA warfarin (10,287 participants). Overall risk of bias and statistical heterogeneity of the studies included were low. </p> <p>The odds of vascular death and ischaemic events were not significantly different between all DTIs and warfarin (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.85 to 1.05). Sensitivity analysis by dose of dabigatran on reduction in ischaemic events and vascular mortality indicated that dabigatran 150 mg twice daily was superior to warfarin although the effect estimate was of borderline statistical significance (OR 0.86, 95% CI 0.75 to 0.99). Sensitivity analyses by other factors did not alter the results. Fatal and non‐fatal major bleeding events, including haemorrhagic strokes, were less frequent with the DTIs (OR 0.87, 95% CI 0.78 to 0.97). Adverse events that led to discontinuation of treatment were significantly more frequent with the DTIs (OR 2.18, 95% CI 1.82 to 2.61). All‐cause mortality was similar between DTIs and warfarin (OR 0.91, 95% CI 0.83 to 1.01). </p> </section> <section id="CD009893-sec-0007"> <h3 class="title" id="CD009893-sec-0007">Authors' conclusions</h3> <p>DTIs were as efficacious as VKAs for the composite outcome of vascular death and ischaemic events and only the dose of dabigatran 150 mg twice daily was found to be superior to warfarin. DTIs were associated with fewer major haemorrhagic events, including haemorrhagic strokes. Adverse events that led to discontinuation of treatment occurred more frequently with the DTIs. We detected no difference in death from all causes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009893-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009893-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009893-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009893-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009893-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009893-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009893-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009893-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009893-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009893-abs-0005" lang="en"> <h3>Direct thrombin inhibitors compared with vitamin K antagonists in people with atrial fibrillation for preventing stroke </h3> <p><b>Question:</b> We wanted to compare the effectiveness and safety of direct thrombin inhibitors (DTIs) with vitamin K antagonists in people with atrial fibrillation (AF) to prevent stroke. </p> <p><b>Background:</b> Non‐valvular atrial fibrillation is a type of irregular heartbeat that arises in a heart with normal valves. It increases the risk of developing blood clots in the heart which can then travel to the brain, leading to a stroke, and to other parts of the body. Warfarin (a vitamin K antagonist) is a drug that prevents the formation of such clots, thus reducing the risk of stroke. However, the need for frequent blood tests to adjust the dose and the risk of bleeding limits the use of warfarin. The oral DTIs represent a potential alternative. We aimed to establish the comparative effectiveness and safety of these new drugs compared with the standard treatment (warfarin) used for long‐term anticoagulation in people with AF. </p> <p><b>Study characteristics</b>: We included eight studies, identified up to October 2013, evaluating the effect of DTIs versus warfarin in people with non‐valvular AF. DTIs included were dabigatran 110 mg or 150 mg twice daily (three studies, 12,355 participants), AZD0837 300 mg once a day (two studies, 233 participants) and ximelagatran 36 mg twice daily (three studies, 3726 participants). Of the total number of participants included in this review 61% were men, and the mean age of participants in all studies was over 70 years. Follow‐up periods after the end of study medication ranged from zero to four weeks. </p> <p><b>Key results:</b> We conducted the analyses excluding ximelagatran because this drug was withdrawn from the market owing to toxic effects on the liver. We evaluated the effectiveness of the treatment by the number of vascular deaths and ischaemic events. We evaluated safety by the number of (1) fatal and non‐fatal major bleeding events, including haemorrhagic strokes, (2) adverse events other than bleeding and ischaemic events that led to treatment discontinuation, and (3) death from all causes. </p> <p>There was no difference in the number of vascular deaths and ischaemic events between all DTIs combined and warfarin, although dabigatran 150 mg twice daily was superior to warfarin for this outcome. Major bleeding events were less frequent with the DTIs, making them a potentially safer alternative to anticoagulation in people at high risk. The adverse events that led participants to discontinue treatment were more frequent with the DTIs. Death from all causes was similar between DTIs and warfarin. </p> <p><b>Quality of the evidence:</b> We judged the quality of all eight included studies to be adequate to address the main objectives of the review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009893-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009893-sec-0092"></div> <h3 class="title" id="CD009893-sec-0093">Implications for practice</h3> <section id="CD009893-sec-0093"> <p>The odds of preventing a vascular death or ischaemic event (including ischaemic stroke, transient ischaemic attack, systemic embolic events and myocardial infarction) did not differ substantially between the direct thrombins inhibitors (DTIs) and vitamin K antagonists (VKAs), meaning that DTIs are as efficacious as VKAs to prevent all these clinically relevant outcomes. Dabigatran 150 mg twice daily was superior to warfarin for this composite endpoint. Fewer major haemorraghic events, including haemorrhagic strokes, were observed with the DTIs, making these new drugs easily administered safe alternatives to adjusted‐dose warfarin. The impact of the higher dose of dabigatran on vascular deaths and ischaemic events is important because it indicates that the advantage of dabigatran compared with warfarin is not limited to effects on bleeding. Thus, in the not infrequent clinical scenario where warfarin administration or monitoring poses significant difficulties, DTIs appear promising. Nonetheless, people on DTIs should still be carefully monitored, as concerns remain with the lack of drug antidote and compliance, given the need for twice daily administration. Several additional factors exist, such as comorbid conditions including reduced renal function, side‐effect profile, cost and patient preference. Therefore, the need to consider the balance of benefit and risk in each individual is no less important than with VKA therapy. </p> </section> <h3 class="title" id="CD009893-sec-0094">Implications for research</h3> <section id="CD009893-sec-0094"> <p>Our review has evaluated all DTIs combined versus warfarin. However, an important gap in the evidence is the lack of comparisons between different drug classes (e.g. DTIs versus Factor Xa inhibitors) and between different drugs within a class. This should be assessed in future research through multicentre randomised controlled trials comparing newer anticoagulants with each other and through network meta‐analyses. Also, the mean evaluation period across studies was about two years. Since anticoagulation in people with non‐valvular AF is long‐term, it is possible that additional adverse effects may arise with more prolonged use. Observational studies and US Food and Drug Administration‐European Medicines Agency pharmacovigilance should be considered to address this issue. </p> <p>Finally, the superiority of dabigatran 150 mg compared with warfarin came from a post hoc sensitivity analysis and was found to be borderline statistically significant. Hence, future studies could assess this finding as a primary analysis. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009893-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009893-sec-0036"></div> <p>Non‐valvular atrial fibrillation (AF) is estimated to affect fewer than 1% of individuals below 50 years of age, increasing to 23.5% in people over 80 years of age (<a href="./references#CD009893-bbs2-0037" title="BenjaminE , WolfP , D'AgostinoR , SilbershatzH , KannelW , LevyD . Impact of atrial fibrillation on the risk of death. Circulation1998;98(10):946‐52. ">Benjamin 1998</a>). Among people with AF, 76% have a moderate to high risk of stroke (<a href="./references#CD009893-bbs2-0063" title="SingerD , AlbersG , DalenJ , FangM , GoA , HalperinJ , et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition).. Chest2008;133(6 Suppl):546S‐592S. ">Singer 2008</a>). Dose‐adjusted warfarin reduces this risk by 62% compared with placebo but increases the risk of intracranial bleeding (<a href="./references#CD009893-bbs2-0050" title="HartRG , PearceLA , AguilarMI . Meta‐analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine2007;146(12):857‐67. ">Hart 2007</a>). Direct thrombin inhibitors (DTIs) constitute a new class of oral anticoagulants under investigation (<a href="./references#CD009893-bbs2-0047" title="FusterV , RydenL , CannomD , CrijnsH . ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation2006;114(7):e257‐354. ">Fuster 2006</a>; <a href="./references#CD009893-bbs2-0064" title="SquizzatoA , DentaliF , SteidlL , AgenoW . New direct thrombin inhibitors. Internal and Emergency Medicine2009;4(6):479‐84. ">Squizzato 2009</a>; <a href="./references#CD009893-bbs2-0066" title="WeitzJI , CrowtherMA . New anticoagulants: current status and future potential. American Journal of Cardiovascular Drugs2003;3(3):201‐9. ">Weitz 2003</a>). </p> <section id="CD009893-sec-0037"> <h3 class="title" id="CD009893-sec-0037">Description of the condition</h3> <p>AF is a cardiac arrhythmia caused by multiple re‐entrant waveforms within the atria of the heart, which impairs atrial contraction. The resulting left atrial stasis can promote thrombus formation and subsequent embolic events including stroke and systemic embolism (<a href="./references#CD009893-bbs2-0044" title="FerroJ . Atrial fibrillation and cardioembolic stroke. Minerva Cardioangiologica2004;52(2):111‐24. ">Ferro 2004</a>; <a href="./references#CD009893-bbs2-0054" title="KimuraK , MinematsuK , YamaguchiT , Japan Multicenter Stroke Investigators' Collaboration (J‐MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischemic stroke. Journal of Neurology, Neurosurgery and Psychiatry2005;76(5):679‐83. ">Kimura 2005</a>). AF increases the risk of stroke four to five times in all age groups (<a href="./references#CD009893-bbs2-0045" title="FribergJ , ScharlingH , GadsbollN , TruelsenT , JensenGB . Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). American Journal of Cardiology2004;94(7):889‐94. ">Friberg 2004</a>; <a href="./references#CD009893-bbs2-0067" title="WolfPA , AbbottRD , KannelWB . Atrial fibrillation: a major contributor to stroke in the elderly; the Framingham Heart Study. Archives of Internal Medicine1987;147(9):1561‐4. ">Wolf 1987</a>). Without anticoagulation therapy, the stroke rate among people with AF can vary from 1.9% to 18% per year, depending on individual characteristics (CHADS₂ score) (<a href="./references#CD009893-bbs2-0048" title="GageBF , VanWalravenC , PearceL , HartRG , KoudstaalPJ ,  BoodeBS ,  etal . Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation2004;110(16):2287–92. ">Gage 2004</a>). </p> </section> <section id="CD009893-sec-0038"> <h3 class="title" id="CD009893-sec-0038">Description of the intervention</h3> <p>DTIs belong to a new class of anticoagulants that were developed as potential alternatives to vitamin K antagonists (VKAs) for chronic anticoagulation in people with non‐valvular AF (<a href="./references#CD009893-bbs2-0055" title="KirchhofP , AuricchioA , BaxJ , CrijnsH , CammJ , DienerHC , et al. Outcome parameters for trials in atrial fibrillation: executive summary. European Heart Journal2007;28(22):2803‐17. ">Kirchhof 2007</a>). DTIs offer fixed oral dosing without the need for coagulation monitoring, as well as rapid onset of action and stable pharmacokinetics with little potential for drug interactions (<a href="./references#CD009893-bbs2-0034" title="BaetzBE , SpinlerSA . Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy2008;28(11):1354‐73. ">Baetz 2008</a>; <a href="./references#CD009893-bbs2-0059" title="PengoV , PegoraroC , IlicetoS . New trends in anticoagulant therapy. Israel Medical Association Journal2004;6(8):479‐81. ">Pengo 2004</a>). Ximelagatran was the first oral DTI to be used clinically but it was withdrawn from the market due to liver toxicity (<a href="./references#CD009893-bbs2-0033" title="AlbersGW , DienerHC , FrisonL , GrindM , HorrowH , NevinsonM , et al. Executive Steering Committee for the SPORTIF III and V Investigators. Trials and tribulations of non‐inferiority: the ximelagatran experience. Journal of the American College of Cardiology2006;48(5):1058‐9. ">Albers 2006</a>; <a href="./references#CD009893-bbs2-0039" title="BoudesPF . The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contempory Clinical Trials2006;27(5):432‐40. ">Boudes 2006</a>; <a href="./references#CD009893-bbs2-0042" title="European Medicines Agency. Press release: Astra Zeneca withdraws its application for ximelagatran 36‐mg film‐coated tablets. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/02/WC500074073.pdf (accessed 4th March 2014). ">EMEA 2006</a>). Dabigatran etexilate is a DTI that was approved by the US Food and Drug Administration (FDA) in October 2010 for stroke prevention in people with non‐valvular AF. Dabigatran reaches its plasmatic peak and begins its anticoagulant action between half an hour and two hours after oral administration (<a href="./references#CD009893-bbs2-0034" title="BaetzBE , SpinlerSA . Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy2008;28(11):1354‐73. ">Baetz 2008</a>). It is primarily eliminated by the kidneys and it is not metabolised by the cytochrome P450 enzyme system in the liver, which yields a better drug interaction profile (<a href="./references#CD009893-bbs2-0043" title="FareedJ , ThethiI , HoppensateadtD . Old versus new oral anticoagulants: focus on pharmacology. Annual Review of Pharmacology and Toxicology2012;52:79‐99. ">Fareed 2012</a>). AZD0837 is another oral DTI under investigation, not yet licensed for clinical use. </p> </section> <section id="CD009893-sec-0039"> <h3 class="title" id="CD009893-sec-0039">How the intervention might work</h3> <p>Thrombin has a central role in thrombogenesis. DTIs act by interfering with the final step of the coagulation cascade, namely, the conversion of fibrinogen to insoluble fibrin by thrombin. </p> </section> <section id="CD009893-sec-0040"> <h3 class="title" id="CD009893-sec-0040">Why it is important to do this review</h3> <p>Although there is much experience with VKA treatment, it has several disadvantages including its narrow therapeutic index and wide variability of anticoagulation intensity, which requires frequent dose adjustments (<a href="./references#CD009893-bbs2-0049" title="GoAS , HylekEM , ChangY , PhillipsKA , HenaultNE , CapraAM , et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomised trials translate into clinical practice?. JAMA2003;290(20):2685‐92. ">Go 2003</a>; <a href="./references#CD009893-bbs2-0060" title="RoseAJ , OzonoffA , HenaultLE , HylekEM . Warfarin for atrial fibrillation in community‐based practice. Journal of Thrombosis and Haemostasis2008;6(10):1647‐54. ">Rose 2008</a>). Despite regular monitoring, 30% to 50% of the time the international normalised ratio (INR) values fall outside the therapeutic target range (<a href="./references#CD009893-bbs2-0053" title="JonesM , McEwanP , MorganCL , PetersJR , GoodfellowJ , CurrieCJ . Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non valvar atrial fibrillation: a record linkage study in a large British population. Heart2005;91(4):340‐7. ">Jones 2005</a>). Moreover, the risk of bleeding remains a pivotal concern with warfarin therapy, particularly among the elderly (<a href="./references#CD009893-bbs2-0058" title="OldgrenJ , AlingsM , DariusH , DienerHC , EikelboomJ , EzekowitzMD , et al. RE‐LY Investigators. Risk for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE‐LY trial. Annals of Internal Medicine2011;155(10):660‐7. ">Oldgren 2011</a>). These limitations result in undertreatment of a considerable proportion of people with AF who remain at high risk for stroke (<a href="./references#CD009893-bbs2-0046" title="FrykmanV , BeermanB , RydéńL , RosenqvistM , Medical Products Agency, Swedish Society of Cardiology. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. European Heart Journal2001;22(20):1954‐9. ">Frykman 2001</a>) and create a need for safer and more convenient alternatives. In this context, the evaluation of the efficacy and safety of the new DTIs is of critical importance. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009893-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009893-sec-0041"></div> <p>To assess (1) the comparative efficacy of long‐term anticoagulation using DTIs versus VKAs on vascular deaths and ischaemic events in people with non‐valvular AF, and (2) the comparative safety of long‐term anticoagulation using DTIs versus VKAs on (a) fatal and non‐fatal major bleeding events including haemorrhagic strokes, (b) adverse events other than bleeding and ischaemic events that lead to treatment discontinuation, and (c) all‐cause mortality in people with non‐valvular AF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009893-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009893-sec-0042"></div> <section id="CD009893-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009893-sec-0044"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing anticoagulation with direct thombin inhibitors (DTIs) versus vitamin K antagonists (VKAs) for preventing cerebral or systemic embolism in people with non‐valvular AF. </p> </section> <section id="CD009893-sec-0045"> <h4 class="title">Types of participants</h4> <p>People with non‐valvular AF and one or more risk factors for stroke.</p> </section> <section id="CD009893-sec-0046"> <h4 class="title">Types of interventions</h4> <p>Administration of DTIs at standard doses (dabigatran 110 mg twice daily and 150 mg twice daily, AZD0837 300 mg twice daily and ximelagatran 36 mg twice daily) compared with VKAs (adjusted‐dose warfarin) for an INR between 2 and 3. </p> <p>Both doses of dabigatran included in this review are available for clinical use. The dose of dabigatran 150 mg twice daily has been approved by the FDA for preventing stroke in people with non‐valvular AF (<a href="./references#CD009893-bbs2-0036" title="BeasleyB , UngerE , TempleR . Anticoagulant options ‐ why the FDA approved a higher but not a lower  dose of dabigatran. New England Journal of Medicine2011;364(19):1788‐90. ">Beasley 2011</a>). The European Society of Cardiology recommends both dabigatran 150 mg twice daily and dabigatran 110 mg twice daily for people at low and high risk of bleeding respectively (<a href="./references#CD009893-bbs2-0040" title="CammAJ . The RE‐LY study: Randomised Evaluation of Long‐term anticoagulant therapY: dabigatran vs. warfarin. European Heart Journal2009;30(21):2554‐5. ">Camm 2009</a>). The dose of ximelagatran 36 mg twice daily was commercially available until 2006 when it was withdrawn from the market owing to safety concerns. We chose to include the dose of AZD0837 300 mg twice daily even though it has not yet been licensed because in the analysis of individual doses it appeared to have the best efficacy and safety profile among the different tested doses. </p> </section> <section id="CD009893-sec-0047"> <h4 class="title">Types of outcome measures</h4> <section id="CD009893-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009893-list-0001"> <li> <p>The composite outcome of vascular deaths and ischaemic events, including non‐fatal ischaemic strokes and transient ischaemic attacks (TIAs), non‐fatal systemic embolic events (SEE) and non‐fatal myocardial infarction (MI). Vascular death is defined as any death related to a vascular cause not including fatal haemorrhages or cardiovascular deaths (e.g. sudden arrhythmia, pump failure). Systemic embolism is defined as any event of acute non‐intracerebral or non‐coronary vascular origin including deep vein thrombosis (DVT) and pulmonary embolism (PE). </p> </li> <li> <p>The composite outcome of fatal or non‐fatal major bleeding events, including haemorrhagic strokes. We did not include minor bleeding events. </p> </li> </ol> </p> </section> <section id="CD009893-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009893-list-0002"> <li> <p>Fatal or non‐fatal adverse events other than haemorrhage and ischaemic events that lead to discontinuation of treatment. </p> </li> <li> <p>Death from all causes during treatment.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009893-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We searched for relevant trials in all languages and, where necessary, arranged translation of trial reports published in languages other than English or Spanish. </p> <section id="CD009893-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register (last searched July 2013). In addition, we searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, May 2013, Issue 5) (<a href="./appendices#CD009893-sec-0098">Appendix 1</a>), MEDLINE (Ovid) (1950 to July 2013) (<a href="./appendices#CD009893-sec-0099">Appendix 2</a>), EMBASE (Ovid) (1980 to October 2013) (<a href="./appendices#CD009893-sec-0100">Appendix 3</a>), and LILACS (Latin American and Caribbean Health Science Literature) (1982 to October 2013) (<a href="./appendices#CD009893-sec-0101">Appendix 4</a>). We also searched ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), Current Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>), TrialResults‐center (<a href="http://www.trialresultscenter.org" target="_blank">www.trialresultscenter.org</a>), Stroke Trials Directory (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) (last searched September 2013). </p> <p>We developed the search strategies for MEDLINE, EMBASE and CENTRAL with the help of the Cochrane Stroke Group Trials Search Co‐ordinator and adapted the MEDLINE search strategy for the other databases. </p> </section> <section id="CD009893-sec-0052"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished and ongoing trials we:</p> <p> <ol id="CD009893-list-0003"> <li> <p>screened the reference lists of relevant articles;</p> </li> <li> <p>identified and handsearched the following relevant journals and the proceedings of relevant conferences (last search: September 2013): Congresses of the European Society of Cardiology, Scientific sessions of the American Heart Association, Heart Rhythm Society and Annual Meeting of the American College of Cardiology; </p> </li> <li> <p>reviewed the websites of the following pharmaceutical companies for clinical trial results: AstraZeneca (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>) and Boehringer‐Ingelheim (<a href="http://www.boehringer-ingelheim.com" target="_blank">www.boehringer‐ingelheim.com</a>). </p> </li> </ol> </p> </section> </section> <section id="CD009893-sec-0053"> <h3 class="title" id="CD009893-sec-0053">Data collection and analysis</h3> <p>All three review authors screened the records obtained from the electronic searches and excluded obviously irrelevant studies. We obtained the full text of the remaining papers and the same three authors selected trials for inclusion based on the selection criteria described previously. We arranged translation of titles and abstracts of articles in languages other than English or Spanish, and if the title and the abstract potentially met the inclusion criteria we had the entire text of the article translated. We resolved any disagreements through discussion and consensus. </p> <section id="CD009893-sec-0054"> <h4 class="title">Selection of studies</h4> <p>All three review authors independently assessed eligibility of studies based on prespecified inclusion and exclusion criteria. We resolved disagreements by discussion and consensus. We listed studies excluded at the full‐text review stage along with the reasons for exclusion. See the study flow chart (Figure 1). </p> </section> <section id="CD009893-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>All three review authors independently extracted data using predesigned abstraction forms. We verified these forms to ensure that all relevant data were included. We compared the abstraction forms with each other to ensure reproducibility between abstractors. </p> </section> <section id="CD009893-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>All three review authors independently assessed the methodological quality of each included study using the domain‐based evaluation tool described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009893-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Quality criteria consisted of (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel (4) blinding of outcome assessment (5) incomplete outcome data addressed, (6) selective reporting and (7) other potential biases. Each author issued a judgement of risk (low, high or uncertain) for each quality criterion. When a rating of high or low would not have been feasible or prudent, we assigned a grade of unclear. We resolved disagreements by discussion. We addressed publication bias using graphical statistics such as funnel plots. See Figure 2 and Figure 3. </p> </section> <section id="CD009893-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>The outcomes were binary and we summarised the dichotomous data using odds ratios (ORs). Results are presented with 95% confidence intervals (CIs). </p> </section> <section id="CD009893-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <p>The included RCTs had a simple parallel group design. In this design, the participants are individually randomised to either the intervention group (DTIs) or the control group (VKAs) and we collected and analysed a single measurement for each outcome from each participant. For phase II studies including multiple treatment arms with different doses of the DTIs, we selected the data from the treatment arm using the standard or intermediate doses. See <a href="#CD009893-sec-0046">Types of interventions</a>. </p> </section> <section id="CD009893-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We complemented data from the final report of included studies with: (1) protocol descriptions (e.g. rationale and design articles), (2) clinical trial registers, (3) editorials and subanalyses of main studies, and (4) FDA briefing documents. If the missing data could not be obtained, then we analysed the available data and noted any assumptions made. We carefully considered missing data when evaluating potential biases and in the interpretation of results. </p> </section> <section id="CD009893-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistical test (<a href="./references#CD009893-bbs2-0051" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>) to ascertain heterogeneity among studies. The I² is expressed as a percentage, and describes the proportion of variability that is due to heterogeneity rather than to sampling error. We categorised heterogeneity as follows: low (I² values less than 25%), moderate (I² above 25% but less than 50%) and high (I² between 50% and 75%). </p> </section> <section id="CD009893-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>We performed a comprehensive search for published, unpublished and ongoing studies that met our eligibility criteria. The evaluation of methodological quality of included studies comprised the assessment of selective reporting. </p> </section> <section id="CD009893-sec-0062"> <h4 class="title">Data synthesis</h4> <p>We used either fixed‐effect or random‐effects models to synthesise the evidence quantitatively, depending on the heterogeneity across studies. For an analysis with low heterogeneity we planned to use a fixed‐effect meta‐analysis. Conversely, for moderate or high heterogeneity we planned to use a random‐effects meta‐analysis. Finally, if the combination of studies resulted in very high heterogeneity (greater than 75%), we did not perform a combined analysis. </p> </section> <section id="CD009893-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Other than the analysis of grouped and individual doses described in the <a href="#CD009893-sec-0064">Sensitivity analysis</a> section, we could not undertake the subgroup analyses prespecified in the protocol due to insufficient data. See <a href="#CD009893-sec-0113">Differences between protocol and review</a>. </p> </section> <section id="CD009893-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analyses:</p> <p> <ol id="CD009893-list-0004"> <li> <p>re‐analysis of data using a different statistical approach (random‐effects instead of fixed‐effect and vice versa); </p> </li> <li> <p>different doses of DTIs: all tested doses grouped and isolated.</p> </li> </ol> </p> <p>Post hoc sensitivity analyses included:</p> <p> <ol id="CD009893-list-0005"> <li> <p>excluding the studies of ximelagatran;</p> </li> <li> <p>evaluating each drug independently;</p> </li> <li> <p>excluding myocardial infarction (MI) from the primary efficacy outcome.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009893-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009893-sec-0065"></div> <section id="CD009893-sec-0066"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009893-sec-0115" title="">Characteristics of included studies</a>; <a href="./references#CD009893-sec-0116" title="">Characteristics of excluded studies</a>. </p> <section id="CD009893-sec-0067"> <h4 class="title">Results of the search</h4> <p>We obtained 1025 records through the searches of the electronic databases and 89 additional references from other sources. After removing duplicate records, we screened 1074 records by title and abstract. We excluded 1042 records as not relevant. We obtained the full text of the remaining 32 papers and of these we excluded 24. Eight studies are included in the qualitative and quantitative synthesis (<a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a>; <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a>; <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>; <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>; <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>; <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a>; <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a>; <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a>). We did not identify any ongoing trials. The flow diagram describing the search process, selection and exclusion is shown in <a href="#CD009893-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009893-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009893-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009893-sec-0068"> <h4 class="title">Included studies</h4> <p>We identified eight randomised controlled trials (RCTs) that met the eligibility criteria, which included a total of 27,557 participants, 26,601 of whom were assigned to standard doses groups and included in the primary analysis. The direct thrombin inhibitors (DTIs) dabigatran 110 mg twice daily and 150 mg twice daily (three studies, 12,355 participants), AZD0837 300 mg once daily (two studies, 233 participants) and ximelagatran 36 mg twice daily (three studies, 3726 participants) were compared to the vitamin K antagonist (VKA) warfarin (10,287 participants). <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> represented 66% of the total population. Three RCTs used dabigatran etexilate (<a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a>; <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>; <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>). Two RCTs used AZD0837: <a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a> used an extended‐release form and <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a> used immediate‐release pills. Three RCTs used ximelagatran (<a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>; <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a>; <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a>). Three included studies were phase III RCTs designed to assess efficacy and safety (<a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>; <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a>; <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a>), while the remaining five were phase II RCTs that evaluated tolerability and safety of different dosages (<a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a>; <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a>; <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a>; <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>; <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>).These latter studies also reported events that were included in the efficacy analysis. All studies were funded by the pharmaceutical industry. </p> <p>From the total number of participants included in this review, 61% were men and the mean age of participants in all studies was over 70 years. The rate of VKA‐naϊve participants (never previously exposed to VKAs) was approximately 50% (range 5% to 100%). The average CHADS₂ score was 2.1 except for <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a> in which the average score was 3. The studies of ximelagatran did not report CHADS₂ scores. In the groups assigned to warfarin, the international normalised ratio (INR) was maintained within the therapeutic range between 57% and 71% of the time. In five studies (<a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a>; <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a>; <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>; <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>; <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>) the different doses of DTIs were administered in a double‐blind modality whereas warfarin was given openly. <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a> and <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> were open‐label for both the DTI and warfarin. <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> used a double‐dummy design to blind the administration of both the intervention and the control drug. In <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>, the three doses of dabigatran used (50, 150, and 300 mg twice daily) were combined in a 3 x 3 factorial fashion with no aspirin, 81 mg or 325 mg aspirin once daily. Aspirin was given openly. </p> <p>The studies planned outcome assessment over 2.8 to 24 months for dabigatran, three to 4.7 months for AZD0837 and three to 20 months for ximelagatran. Follow‐up periods after discontinuation of study medication ranged from zero to four weeks. </p> </section> <section id="CD009893-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 24 studies. We excluded 15 studies because they studied populations other than people with AF (e.g. healthy individuals, people with DVT, with mechanical heart valves, haemodialysis, people undergoing elective percutaneous coronary intervention, people with acute coronary syndrome) (<a href="./references#CD009893-bbs2-0012" title="ErikssonBI ,  DahlOE ,  BüllerHR ,  HettiarachchiR ,  RosencherN ,  BravoML ,  etal . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Journal of Thrombosis and Haemostasis2005;3(1):103‐11. ">BISTRO 2005</a>; <a href="./references#CD009893-bbs2-0013" title="EikelboomJW , ConnollySJ , BrueckmannM , GrangerCB , KappeteinAP , MackMJ , et al. Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine2013;369(13):1206‐14. ">Eikelboom 2013</a>; <a href="./references#CD009893-bbs2-0015" title="ErikssonBI ,  DahlOE ,  RosencherN ,  KurthAA ,  Van DijkCN ,  FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ">Eriksson 2007</a>; <a href="./references#CD009893-bbs2-0016" title="WallentinL ,  WilcoxRG ,  WeaverWD ,  EmanuelssonH ,  GoodvinA ,  NyströmP ,  etal . Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet2003;362(9386):789‐97. ">ESTEEM 2003</a>; <a href="./references#CD009893-bbs2-0022" title="NCT01225822 . BIBR 1048 dose range finding study in prevention of venous thromboembolism in patients with primary elective total hip or knee replacement surgery. http://clinicaltrials.gov/ct2/show/NCT01225822(accessed September 2013). ">NCT01225822</a>; <a href="./references#CD009893-bbs2-0018" title="NCT00152971 . Dabigatran etexilate vs enoxaparin in prevention of venous thromboembolism (VTE) post total knee replacement. http://clinicaltrials.gov/ct2/show/NCT00152971?term=Dabigatran+etexilate+vs+enoxaparin+in+prevention+of+venous+thromboembolism+%28VTE%29+post+total+knee+replacement&amp;rank=1(accessed September 2013). ">NCT00152971</a>; <a href="./references#CD009893-bbs2-0019" title="NCT00246025 . A study of BIBR 1048 in prevention of venous thromboembolism in patients with TKR surgery. http://clinicaltrials.gov/ct2/show/NCT00246025?term=A+study+of+BIBR+1048+in+prevention+of+venous+thromboembolism+in+patients+with+TKR+surgery&amp;rank=1(accessed September 2013). ">NCT00246025</a>; <a href="./references#CD009893-bbs2-0020" title="NCT00680186 . Phase III study testing efficacy and safety of oral dabigatran etexilate vs warfarin for 6 months. Treatment for acute symptomatic venous thromboembolism (VTE). http://clinicaltrials.gov/ct2/show/NCT00680186?term=oral+dabigatran+etexilate+vs+warfarin&amp;rank=1(accessed September 2013). ">NCT00680186</a>; ; <a href="./references#CD009893-bbs2-0023" title="Van deWerfF ,  BrueckmannM ,  ConnollySJ ,  FriedmanJ ,  GrangerCB ,  HärtterS ,  etal . A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomised, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE‐ALIGN). Americal Heart Journal2012;163(6):931‐7. ">RE‐ALIGN 2012</a>; <a href="./references#CD009893-bbs2-0024" title="SchulmanS ,  KearonC ,  KakkarAK ,  MismettiP ,  SchellongS ,  ErikssonH ,  etal . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342‐52. ">RECOVER 2009</a>; <a href="./references#CD009893-bbs2-0025" title="OldgrenJ ,  BudajA ,  GrangerCB ,  KhderY ,  RobertsJ ,  SiegbahnA ,  etal . Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomised, double‐blind, phase II trial. European Heart Journal2011;32(22):2781‐9. ">REDEEM 2011</a>; <a href="./references#CD009893-bbs2-0027" title="ErikssonBI ,  DahlOE ,  RosencherN ,  KurthAA ,  van DijkCN ,  FrostickSP ,  etal . Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomised trial. Journal of Thrombosis and Haemostasis2007;5(11):2178‐85. ">REMODEL 2007</a>; <a href="./references#CD009893-bbs2-0028" title="ErikssonBI ,  DahlOE ,  HuoMH ,  KurthAA ,  HantelS ,  HermanssonK ,  etal . Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II*). A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. ">RENOVATE 2011</a>; <a href="./references#CD009893-bbs2-0030" title="SchulmanS ,  KearonC ,  KakkarAK ,  SchellongS ,  ErikssonH ,  BaanstraD ,  etal . Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709‐18. ">Schulman 2013</a>; <a href="./references#CD009893-bbs2-0032" title="VranckxP ,  VerheugtFW ,  De MaatMP ,  UlmansVA ,  RegarE ,  SmitsP ,  etal . A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention2013;8(9):1052‐60. ">Vranckx 2013</a>). We excluded six studies (<a href="./references#CD009893-bbs2-0009" title="ConnollyS , PoqueJ , HartR , PrefferM , HohnloserS , ChrolavisciusS , et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet2006;367(9526):1903‐12. ">ACTIVE 2006</a>; <a href="./references#CD009893-bbs2-0010" title="BousserMG , BouthierJ , BüllerHR , CohenAT , CrijnsH , DavidsonBL , et al. Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open‐label, non‐inferiority trial. Lancet2008;371(9609):315‐21. ">Amadeus Investig 2008</a>; <a href="./references#CD009893-bbs2-0011" title="GrangerCB ,  AlexanderJH ,  McMurrayJJ ,  LopesRD ,  HylekEM ,  HannaM ,  etal . Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2011;365(11):981‐92. ">ARISTOTLE 2011</a>; <a href="./references#CD009893-bbs2-0014" title="WeitzJI ,  ConnollySJ ,  PatelI ,  SalazarD ,  RohatagiS ,  MendellJ ,  etal . Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis2010;104(3):633‐41. ">ENGAGE AF 2010</a>; <a href="./references#CD009893-bbs2-0017" title="ConnollySJ ,  EikelboomJ ,  DorianP ,  HohnloserSH ,  GretlerDD ,  SinhaU ,  etal . Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomised, dose‐ranging study (Explore‐Xa). European Heart Journal2013; Vol. 34, issue 20:1498‐505. ">EXPLORE Xa 2013</a>; <a href="./references#CD009893-bbs2-0029" title="PatelMR ,  MahaffeyKW ,  GargJ ,  PanG ,  SingerDE ,  HackeW ,  etal . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine2011;365(10):883‐91. ">ROCKET 2011</a>) because they did not use a DTI as the intervention. We excluded one study for not using warfarin as the comparison (<a href="./references#CD009893-bbs2-0021" title="NCT00904800 . AZD0837 Extended Release (ER) Japan Study. http://clinicaltrials.gov/show/NCT00904800(accessed September 2013). ">NCT00904800</a>). The international multicentre <a href="./references#CD009893-bbs2-0026" title="ConnollySJ . Randomised comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the RELY‐ABLE double‐blind randomised trial. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2974&amp;sKey=94d74361‐5616‐4a16‐8a8e‐a3739885329a&amp;cKey=770e5366‐02c1‐4314‐9a37‐76ab178d193b&amp;mKey=14145d5b‐f96b‐4354‐8237‐8f0937744ba4 [American Heart Association Scientific Sessions] 7 November 2012. ">RELY ABLE 2012</a> study followed 5851 participants on dabigatran for a further 28 months after completion of <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>. We excluded this study because it had no comparison group and participants randomised to warfarin in the original study were not eligible for inclusion. Moreover, participants continuing in <a href="./references#CD009893-bbs2-0026" title="ConnollySJ . Randomised comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the RELY‐ABLE double‐blind randomised trial. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2974&amp;sKey=94d74361‐5616‐4a16‐8a8e‐a3739885329a&amp;cKey=770e5366‐02c1‐4314‐9a37‐76ab178d193b&amp;mKey=14145d5b‐f96b‐4354‐8237‐8f0937744ba4 [American Heart Association Scientific Sessions] 7 November 2012. ">RELY ABLE 2012</a> differed in several respects from those who did not: continuing participants were less likely to have permanent AF, less likely to have heart failure and less likely to have had a major clinical event during the original study. <a href="./references#CD009893-bbs2-0031" title="AstraZeneca . Long‐term treatment with the oral direct thrombin inhibitor H 376/95, compared to warfarin, as stroke prophylaxis in patients with atrial fibrillation. An open 10‐year follow‐up study. Final report at 7 years (Supplement to 5‐year interim analysis report). AstraZeneca Synopsis 8 December 2006. ">SPORTIF IV 2006</a> is a long‐term follow‐up study of people who participated in <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>. It was stopped prematurely following an adverse event report of serious liver injury in the EXTEND clinical trial. We excluded the <a href="./references#CD009893-bbs2-0031" title="AstraZeneca . Long‐term treatment with the oral direct thrombin inhibitor H 376/95, compared to warfarin, as stroke prophylaxis in patients with atrial fibrillation. An open 10‐year follow‐up study. Final report at 7 years (Supplement to 5‐year interim analysis report). AstraZeneca Synopsis 8 December 2006. ">SPORTIF IV 2006</a> study owing to methodological concerns as it introduced significant bias: only people completing the first and seventh visit of <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a> were eligible for the study, outcome assessment lost blinding and all three different dose arms were combined into a single dose of ximelagatran 36 mg bid and analysed together. </p> </section> </section> <section id="CD009893-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD009893-fig-0002">Figure 2</a>, <a href="#CD009893-fig-0003">Figure 3</a>, <a href="#CD009893-fig-0004">Figure 4</a> and <a href="#CD009893-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD009893-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: Efficacy outcome: Vascular deaths plus ischaemic events" data-id="CD009893-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: Efficacy outcome: Vascular deaths plus ischaemic events</p> </div> </div> </div> <div class="figure" id="CD009893-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: Safety outcome: Fatal and non‐fatal haemorrhages" data-id="CD009893-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: Safety outcome: Fatal and non‐fatal haemorrhages</p> </div> </div> </div> <div class="figure" id="CD009893-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009893-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009893-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009893-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009893-sec-0071"> <h4 class="title">Allocation</h4> <p>Seven of the included studies achieved randomisation sequence through a computerised interactive system, and three of them maintained the allocation concealment in the same way. <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a>, <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a> and <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> trials did not mention how allocation concealment was maintained after the randomisation. <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a> did not specify how the randomisation sequence or allocation concealment was done. </p> </section> <section id="CD009893-sec-0072"> <h4 class="title">Blinding</h4> <p>Participants taking warfarin needed constant INR monitoring. Therefore, blinding of both intervention and control groups was not done in most studies. However, the different doses of DTI were blinded to the physician and to the participant. Only <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> used a double‐dummy design to maintain blinding of both DTI and warfarin. <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a> and <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> were open‐label for both intervention and control groups. In <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>, <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>, <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a>, <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> and <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> endpoint adjudication was done by an independent committee blinded to treatment status following the PROBE design in an effort to compensate for open warfarin. </p> </section> <section id="CD009893-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> showed a rate of discontinuation of treatment of 19.6% and 15% in the dabigatran and warfarin groups respectively. The reasons for discontinuation were uncertain for 208 participants in the dabigatran group and 200 in the warfarin group. This study reported that only 20 (0.11%) participants interrupted follow‐up. In <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a> 47 (18.2%) participants discontinued assigned treatment prematurely. Reasons for discontinuation remained uncertain in 24 participants. <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> reported premature discontinuation of study treatment in 309 (18%) participants in the ximelagatran group and 246 (14%) participants in the warfarin group. The reasons for discontinuation were uncertain for 125 participants in the ximelagatran group and 124 in the warfarin group. In this study interrupted follow‐up was seen in 138 (4%) participants. Status could not be ascertained in 18 of 78 participants assigned to ximelagatran and 17 of 60 participants assigned to warfarin. <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> reported that 37% and 33% discontinued treatment prematurely in the ximelagatran and warfarin groups respectively. This study reported a total of 226 (6%) participants who interrupted follow‐up. Status remained uncertain for 23 of them. <a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a> also had a significant percentage of discontinuation of treatment in the DTI group (16.8%) compared with that of the warfarin group (7.9%). However, the overall follow‐up interruption was less than 10% (8.9% for AZD0837 and 4.7% for warfarin). The treatment discontinuation percentages in the other studies were: <a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a>: 6.4% and <a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a>: 7.5%. <a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a> did not report the number of discontinuations. </p> <p>Reported outcomes in <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> were complemented with data from a RE‐LY update publication, Conolly 2010 (included in the <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> references), which reported additional primary efficacy outcome events recorded during routine clinical site closure visits after the database was locked. Additionally, we used data from a briefing document submitted to the FDA by Boehringer Ingelheim, Pharmaceuticals Boehringer Ingelheim 2010 (included in the <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> references) to obtain the exact number of individual outcomes included in composite endpoints. </p> <p>We made assumptions when missing data could not be obtained and when reported outcomes left room for interpretation. All assumptions followed unified criteria across studies and were made before the pooled analysis was carried out. These are detailed as follows: </p> <section id="CD009893-sec-0074"> <h5 class="title">Dabigatran studies</h5> <p><a href="./references#CD009893-bbs2-0004" title="EzekowitzMD , ReillyPA , NehmizG , SimmersTA , NagarakantiR , Parcham‐AzadK , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). American Journal of Cardiology2007;100(9):1419‐26. ">PETRO 2007</a> </p> <p>502 participants were randomised, 13 of whom were included twice in the safety analysis of the study owing to a change in their aspirin dose, reaching a total of 515 participants analysed. In our security analysis, we only included the 502 initially randomised participants. </p> <p>Two deaths in the dabigatran group were reported in the study report on the pharmaceutical company website: one of them was due to heart failure and the other was due to mesenteric ischaemia. Neither is mentioned in the published report. We included both deaths in our analysis as death from all causes. We did not include the death attributed to systemic embolism in the efficacy analysis because we could not elucidate the dosage arm to which it belonged. </p> <p>One participant had a peripheral embolism and an ischaemic stroke, which counted as two separate events in our efficacy analysis. </p> <p><a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> </p> <p>We included the number of strokes with uncertain classifications (seven for dabigatran 110 mg twice daily, nine for dabigatran 150 mg twice daily and 10 for warfarin) in the primary efficacy outcome. </p> <p>We included both clinical and silent MI in the primary analysis.</p> <p>We included deaths classified as vascular from unknown causes (46 for dabigatran 110 mg twice daily, 41 for dabigatran 150 mg twice daily and 46 for warfarin) as vascular deaths. </p> <p><a href="./references#CD009893-bbs2-0002" title="NCT01136408 . Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non‐valvular atrial fibrillation in comparison to warfarin. http://www.clinicaltrials.gov/ct2/show/NCT01136408accessed 2007 (reported). [NCT01136408] ">NCT01136408</a> </p> <p>We considered a participant who presented with an ischaemic stroke with haemorrhagic conversion only as an ischaemic event. </p> </section> <section id="CD009893-sec-0075"> <h5 class="title">AZD0837 studies</h5> <p><a href="./references#CD009893-bbs2-0001" title="LipGY , RassmusenLH , OlssonSB , JensenEC , PerssonAL , ErickssonU , et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation: a randomised dose‐guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal2009;30(23):2897‐907. ">Lip 2009</a> </p> <p>We counted clinically relevant bleeding events in the safety analysis.</p> <p>One participant in the warfarin group presented one major bleeding and one clinically relevant bleeding, which we considered as two different events in our safety analysis. </p> <p>We considered one death due to haemorrhage after a skull fracture as a death from other causes. </p> <p><a href="./references#CD009893-bbs2-0003" title="OlssonSB , RassmusenLH , TveitA , JensenE , WessmanP , PanfilovS , et al. Safety and tolerability of an immediate‐release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis2010;103(3):604‐12. ">Olsson 2010</a> </p> <p>We included a participant with MI, considered as an adverse event by the study authors, in the efficacy analysis. A participant who died of sudden chest pain and for whom an autopsy was not performed is considered in our analysis as a death from other causes. </p> </section> <section id="CD009893-sec-0076"> <h5 class="title">Ximelagatran studies</h5> <p><a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a> </p> <p>No assumptions.</p> <p><a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> </p> <p>One participant had both initial ischaemic and subsequent haemorrhagic stroke. The former is included in the efficacy analyses and the latter in the safety analysis as two separate events. </p> <p>The 10 deaths reported in participants who had already terminated the study are not accounted for in any analysis. </p> <p><a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> </p> <p>One participant who had two ischaemic strokes is counted twice in our efficacy analysis.</p> </section> </section> <section id="CD009893-sec-0077"> <h4 class="title">Selective reporting</h4> <p>All three review authors assessed selective reporting by cross‐checking the results reported in the original articles with those obtained from online trial registers and from the reports of pharmaceutical company websites. We included all reported outcome events in the analyses. </p> </section> <section id="CD009893-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>None detected.</p> </section> </section> <section id="CD009893-sec-0079"> <h3 class="title" id="CD009893-sec-0079">Effects of interventions</h3> <p>Tests for statistical heterogeneity suggested low variability in treatment effects across studies for all outcomes analysed. However, we judged clinical heterogeneity to be moderate owing to differences in methodological aspects and variation in definitions of reported outcomes across studies. </p> <section id="CD009893-sec-0080"> <h4 class="title">Primary outcomes</h4> <section id="CD009893-sec-0081"> <h5 class="title">Efficacy analysis</h5> <p>See <a href="./references#CD009893-fig-0006" title="">Analysis 1.1</a> and <a href="./references#CD009893-fig-0008" title="">Analysis 3.1</a> </p> <p>Vascular deaths and ischaemic events (including ischaemic strokes/transient ischaemic attacks (TIAs), non‐fatal systemic embolic events (SEE) and non‐fatal myocardial infarction (MI)) were not significantly different between all DTIs and warfarin (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.85 to 1.05). The analysis of individual drugs within the class showed similar results for dabigatran versus warfarin (OR 0.92, 95% CI 0.82 to 1.04), AZD0837 versus warfarin (OR 0.52, 95% CI 0.06 to 4.72) and ximelagatran versus warfarin (OR 1.02, 95% CI 0.83 to 1.26). Sensitivity analyses of individual doses of dabigatran showed that numerically fewer events were observed for both dabigatran doses but only dabigatran 150 mg twice daily was significantly superior to warfarin for the primary endpoint (OR 0.86, 95% CI 0.75 to 0.99). When we excluded the studies examining ximelagatran, the results were unchanged. The analysis excluding MI favoured the DTIs slightly without reaching statistical significance (OR 0.89, 95% CI 0.79 to 1.00). </p> </section> <section id="CD009893-sec-0082"> <h5 class="title">Safety analysis</h5> <p>See <a href="./references#CD009893-fig-0007" title="">Analysis 2.1</a> and <a href="./references#CD009893-fig-0009" title="">Analysis 4.1</a> </p> <p>Fatal and non‐fatal major haemorrhages, including haemorrhagic strokes, occurred less frequently with the DTIs compared with VKAs (OR 0.87, 95% CI 0.78 to 0.97). The sensitivity analyses revealed that ximelagatran (OR 0.71, 95% CI 0.55 to 0.92) and the individual dose of dabigatran 110 mg bid (OR 0.82, 95% CI 0.71 to 0.94) contributed most to this result. Numerically, fewer events were observed with all other comparisons (dabigatran both doses versus warfarin, dabigatran 150 mg twice daily versus warfarin, AZD0837 versus warfarin), although none reached statistical significance. </p> </section> </section> <section id="CD009893-sec-0083"> <h4 class="title">Secondary outcomes</h4> <section id="CD009893-sec-0084"> <h5 class="title">Adverse events</h5> <p>See <a href="./references#CD009893-fig-0010" title="">Analysis 5.1</a> and <a href="./references#CD009893-fig-0011" title="">Analysis 5.2</a> </p> <p>We excluded studies of ximelagatran for this analysis because this drug was withdrawn from the market due to adverse effects on liver function. Importantly, the risk of transaminase elevation to three times the upper limit of normal was not increased either with dabigatran all doses versus warfarin (OR 0.91, 95% CI 0.74 to 1.13) or AZD0837 all doses versus warfarin (OR 1.52, 95% CI 0.60 to 3.86). </p> <p>Adverse events other than bleeding and ischaemic events that led to treatment discontinuation were significantly more frequent with the DTIs compared with VKAs (OR 2.18, 95% CI 1.82 to 2.61). </p> <p>Serious adverse events were also more frequent in the DTI group (OR 1.31, 95% CI 1.09 to 1.56); these were significantly more frequent with dabigatran (OR 1.35, 95% CI 1.12 to 1.63) but not with AZD0837 (OR 0.99, 95% CI 0.57 to 1.71). </p> </section> <section id="CD009893-sec-0085"> <h5 class="title">All‐cause mortality</h5> <p>See <a href="./references#CD009893-fig-0013" title="">Analysis 7.1</a> </p> <p>Death from all causes occurred to a similar extent in both groups (OR 0.91, 95% CI 0.83 to 1.01). Death rates were slightly lower in the DTI group. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009893-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009893-sec-0086"></div> <section id="CD009893-sec-0087"> <h3 class="title" id="CD009893-sec-0087">Summary of main results</h3> <p>Deaths attributed to vascular causes and total ischaemic events (including ischaemic stroke/transient ischaemic attacks (TIAs), non‐fatal systemic embolic events (SEE) and non‐fatal myocardial infarction (MI)) were not significantly different between direct thrombin inhibitors (DTIs) and warfarin. Importantly, the analysis of individual doses showed that dabigatran 150 mg was superior to warfarin for this same endpoint. </p> <p>Bleeding events ‐ namely fatal and non‐fatal haemorrhages including haemorrhagic strokes ‐ were significantly lower with the DTIs. The overall estimate was mainly influenced by ximelagatran and by the dose of dabigatran 110 mg twice daily. </p> <p>Other outcomes evaluated including adverse events that led to discontinuation of treatment were significantly more frequent in the DTI group. Deaths from all causes were comparable between the DTIs and warfarin. </p> </section> <section id="CD009893-sec-0088"> <h3 class="title" id="CD009893-sec-0088">Overall completeness and applicability of evidence</h3> <p>Several aspects of this review attest to its completeness: (1) we conducted a thorough search and included data from published and unpublished studies in the analysis; (2) <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> was complemented with its update publication by Conolly 2010 (included in <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> references) and by the briefing document prepared by Boehringer Ingelheim Pharmaceuticals for the FDA (Boehringer Ingelheim 2010 ‐ included in <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> references), allowing us to break down composite endpoints accurately with minimal assumptions. </p> <p>The assessment of the external validity of our results should take into consideration the following. </p> <p> <ol id="CD009893-list-0006"> <li> <p>The eight studies that met the eligibility criteria were considered adequate to address the main objectives of the review. However, studies varied in important aspects: (a) design; (b) number of randomised participants; (c) duration of study, and (d) definitions of primary and secondary outcomes. </p> </li> <li> <p>All studies were conducted at multiple sites and included participants from the US and Canada, Europe, Asia and Australia. However, fewer black people and Hispanics were enrolled compared to white people and Asians. </p> </li> <li> <p>Populations were broadly similar for important participant characteristics relevant to the treatment in evaluation (age, stroke severity, type of atrial fibrillation (AF), exclusion of people with marked renal impairment) but they varied in other characteristics such as percentage of vitamin K antagonist (VKA)‐naïve participants included or concomitant antiplatelet therapy. </p> </li> <li> <p>Time in the therapeutic range (TTR) varied across studies and across different sites within a given study. However, mean TTR was compatible with the one seen in sites with good control of warfarin therapy in everyday clinical practice (<a href="./references#CD009893-bbs2-0035" title="BakerWL , CiosDA , SanderSD , ColemanCI . Meta‐analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. Journal of Managed Care Pharmacy2009;15(3):244‐52. ">Baker 2009</a>), thus avoiding underestimation of the benefits of the standard therapy. </p> </li> </ol> </p> <p>Although challenging for combined analysis, the clinical heterogeneity across studies better supports the external validity of the results as this variation in participant populations is more likely to reflect practice in the real world. </p> </section> <section id="CD009893-sec-0089"> <h3 class="title" id="CD009893-sec-0089">Quality of the evidence</h3> <p>We included eight RCTs involving 27,623 participants and three DTIs. Studies were heterogeneous in their individual quality assessment; see <a href="#CD009893-fig-0004">Figure 4</a> and <a href="#CD009893-fig-0005">Figure 5</a>. They also varied in design (phase II and phase III), primary and secondary analyses (intention‐to‐treat (ITT) versus per protocol (PP)) and displayed some diversity in the reporting of outcomes. Nonetheless, all eight studies were judged to be adequate to address the main objectives of the review. </p> <p><a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> and <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> analysed all randomised participants according to the ITT principle for primary outcomes. <a href="./references#CD009893-bbs2-0006" title="PetersenP , GrindM , AdlerJ , SPORTIF II Investigators. Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2003;41(9):1145‐51. ">SPORTIF II 2003</a> and <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> describe an ITT analysis but three participants from each study were randomised and not analysed. Overall, 16 participants were randomised but not analysed. The remaining four studies performed a PP analysis only including participants who took at least one dose of study treatment. Secondary outcomes from <a href="./references#CD009893-bbs2-0007" title="OlssonSB ,  Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non‐valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet2003;362(9397):1691‐8. ">SPORTIF III 2003</a> and <a href="./references#CD009893-bbs2-0008" title="AlbersGW ,  DienerHC ,  FrisonL ,  GrindM ,  NevinsonM ,  PartridgeS ,  etal . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA2005;293(6):690‐8. ">SPORTIF V 2005</a> included in the safety analysis were based on an on‐treatment (OT) population that allowed a maximum continuous interruption of 30 days (or up to 60 days total) without study medication. Primary safety analyses in <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> used the randomised set (ITT), and sensitivity analyses using the safety dataset (OT) were performed. </p> </section> <section id="CD009893-sec-0090"> <h3 class="title" id="CD009893-sec-0090">Potential biases in the review process</h3> <p>The risk of having introduced significant bias into the review process is small owing to the fact that all three review authors independently performed study selection, data abstraction and assessment of risk of bias, and cross‐checked them for reproducibility. Added to this, we carried out a comprehensive electronic search complemented with various other sources to minimise overall assumptions. </p> <p>A limitation of our review is the lack of sufficient data to perform head‐to‐head comparisons between different DTIs. Combining all of them may introduce bias to both the efficacy and safety analyses, as we observed important differences between drugs that were not explained by drug class, such as the hepatotoxicity seen with ximelagatran that was not seen with the other DTIs, and some unexplained variations in bleeding effects across studies. </p> <p>Another limitation is the relatively short evaluation periods. Anticoagulation in the AF population is intended to be long‐term, and there is therefore a chance that additional adverse events arise with longer periods of treatment. Moreover, people with AF tend to be older and to have more comorbidities and polypharmacy, which increases their risk of developing adverse events. </p> <p>Importantly, a single study (<a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>) represented 75% of the population analysed in our primary results. The dominant effect that this large study has on the overall estimates should be considered in the interpretation of results. Important differences could be present but undetected, given the smaller samples of the other studies. </p> <p>Finally, we performed several post hoc sensitivity analyses, which may appear to introduce bias. However, the rationale for each analysis is extensively discussed and the findings clearly help in the interpretation of the protocol‐driven composite endpoints. </p> <p>Publication bias must be considered due to the asymmetry of funnel plots and to the fact that no studies were found published in a language other than English. </p> </section> <section id="CD009893-sec-0091"> <h3 class="title" id="CD009893-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>DTIs represent a major advance in stroke prevention in people with non‐valvular AF, as results from our analyses indicate a trend towards similar ‐ and perhaps superior ‐ effectiveness and increased safety. These results are in agreement with the findings from other recently published meta‐analyses: <a href="./references#CD009893-bbs2-0041" title="CapodannoD , CapranzanoP , GiacchiG , CalviV , TamburinoC . Novel oral anticoagulants versus warfarin in non‐valvular atrial fibrillation: a meta‐analysis of 50,578 patients. International Journal of Cardiology2012;167(4):1237‐41. [DOI: 10.1016/j.ijcard.2012.03.148] ">Capodanno 2012</a>, <a href="./references#CD009893-bbs2-0056" title="LipGY , LarsenTB , SkjøthF , RasmussenLH . Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Journal of the American College of Cardiology2012;60(8):738‐46. ">Lip 2012</a> and <a href="./references#CD009893-bbs2-0057" title="MillerCS , GrandiSM , ShimonyA , FilionKB , EisenbergMJ . Meta‐analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. American Journal of Cardiology2012;110(3):453‐60. ">Miller 2012</a>. However, these meta‐analyses included drug classes other than DTIs, such as Factor Xa inhibitors, which are beyond the scope of our review. </p> <p>When comparing our results with those from individual trials, it is important to consider that our primary outcomes were constructed in a different way from those from the original studies. The most relevant difference is that we excluded haemorrhagic stroke from our primary efficacy outcome. The rationale behind this exclusion is that AF does not cause haemorrhagic stroke itself, but anticoagulants do. Moreover, haemorrhagic stroke is not prevented by anticoagulants but rather is associated with their use. Therefore, haemorrhagic stroke belongs more appropriately to the primary safety outcome. The introduction of haemorrhagic stroke in the primary safety endpoint rather than in the primary efficacy endpoint does not undermine its critical clinical relevance. It merely places it where it more appropriately belongs. </p> <p>For our composite primary efficacy endpoint of vascular deaths and ischaemic events, we found no difference between DTIs and warfarin. However, the sensitivity analysis for individual doses revealed that dabigatran 150 mg twice daily was superior to warfarin for this same endpoint. This is a concordance with the results from <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> where the higher dose of dabigatran was found to be superior to warfarin for their primary efficacy outcome of stroke and SEE as well as for their outcome of vascular deaths, particularly those due to strokes. Importantly, our analysis shows that the benefits of dabigatran over warfarin are maintained even after removing the influence of including haemorrhagic strokes in the comparison. </p> <p>The inclusion of vascular deaths in our primary efficacy endpoint is also clinically relevant because death may act as a competing risk factor for stroke/SEE (<a href="./references#CD009893-bbs2-0061" title="SchatzkinA ,  SludE . Competing risks bias arising from an omitted risk factor. American Journal of Epidemiology1989;129(4):850‐6. ">Schatzkin 1989</a>). In a geriatric population with considerable comorbidities, the competing risk of death is especially high (<a href="./references#CD009893-bbs2-0038" title="BerryS , NgoL , SamelsonE , KielD . Competing risk of death: an important consideration in studies of older adults. Journal of the American Geriatric Society2010;58(4):783‐7. ">Berry 2010</a>). The inclusion of death in a composite endpoint is one way of addressing competing risks. </p> <p>The efficacy endpoint in our review also included MI. The inclusion of this outcome in the composite endpoint can be controversial as it can be argued that the pathophysiology of MI differs from that of stroke and other embolic events. However, we deemed this inclusion appropriate based on its clinical relevance and the fact that a recent meta‐analysis of seven trials that evaluated dabigatran for various indications found a higher risk of MI compared with warfarin (<a href="./references#CD009893-bbs2-0065" title="UchinoK , HernandezAV . Dabigatran association with higher risk of acute coronary events. Meta‐analysis of non‐inferiority randomised control trial. Archives of Internal Medicine2012;172(5):397‐402. ">Uchino 2012</a>). Also, in the <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> trial, the frequency of MI was greater in participants receiving dabigatran than in those treated with warfarin. We performed a sensitivity analysis excluding MI to assess the impact of having included this outcome in the comparison. As expected, the results tended to favour the DTIs but without reaching statistical significance. </p> <p>We also considered pulmonary embolism (PE) and deep vein thrombosis (DVT) in our primary analysis as systemic embolic events. The consideration was based on the fact that systemic embolism was defined in the largest included study as an acute non‐intracerebral and non‐coronary vascular event. Although the pathophysiology of arterial and venous thrombosis differs in many aspects, the inclusion of these events in the composite outcome seems reasonable per study definitions. <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> showed slightly higher rates of PE events in both dabigatran groups compared with warfarin but the overall number of these events was low. Both MI and PE were considered as efficacy outcomes in <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> but the authors did not include either of them in the primary efficacy analysis. This is important because the efficacy of the DTI was comparable to that of warfarin in our analysis even after the introduction of MI and PE in the composite endpoint. </p> <p>Our safety analysis was designed to evaluate fatal and non‐fatal haemorraghic events referring to major bleeds rather than overall bleeding events, because major bleeds carry important clinical consequences relevant to health professionals when deciding whether or not to use an anticoagulant. A reduction in major bleeding is of particular clinical relevance, as there is increasing evidence to support a significant association between a major haemorrhagic event and adverse prognosis as indicated by an increased risk of death in people with AF (<a href="./references#CD009893-bbs2-0062" title="SharmaPS , BoruahP , AhmedI , PancholyS . Bleeding as important as ischemic stroke in predicting mortality in atrial fibrillation. Journal of the American College of Cardiology2012;59(13):E672. ">Sharma 2012</a>). In our safety analysis, DTIs were found to be superior to warfarin with fewer fatal and non‐fatal haemorraghic events including haemorrhagic strokes. The sensitivity analyses showed that this favourable result was mainly influenced by ximelagatran and dabigatran at the dose of 110 mg twice daily. Interestingly, although numerically fewer major bleeding events were seen in all three SPORTIF trials, none of the individual studies found a statistically significant difference between the DTI and warfarin. In contrast, <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a> did report a significant reduction in the occurrence of major bleeding events with both doses of dabigatran compared with warfarin. </p> <p>In the evaluation of new drugs, the assessment of adverse events is fundamental. However, the possibility of researcher bias needs to be considered in this analysis. Researcher bias refers to investigators having more stringent discontinuation criteria for the new treatment in comparison with a standard drug with which they have more experience and feel more comfortable. Since warfarin was given in an open‐label fashion in most studies, this bias could be important. Our analysis included only events that led to treatment discontinuation because participant compliance with long‐term treatment is of critical importance in dealing with chronic conditions like stroke prevention in AF. Our analysis showed that the adverse events leading to treatment discontinuation occurred more frequently with the DTIs compared with warfarin. The most frequent adverse events were gastrointestinal complaints. Interestingly, the analysis of individual drugs showed that adverse events leading to treatment discontinuation were significantly more frequent with dabigatran than with AZD0837. </p> <p>Finally, we found all‐cause mortality to be comparable between DTIs and VKAs. The results are in agreement with <a href="./references#CD009893-bbs2-0005" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , ParekhA , et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139‐51. ConnollySJ , EzekowitzMD , YusufS , ReillyPA , WallentinL . Newly identified events in the RE‐LY trial. New England Journal of Medicine2010;363(19):1875‐6. FDA Advisory Committee. Dabigatran briefing document [Boehringer Ingelheim]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 4th March 2014)2010:1‐168. ">RE‐LY 2009</a>, where fewer overall deaths were observed in both dabigatran groups compared with the warfarin group, although this difference did not reach statistical significance. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009893-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009893-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: Efficacy outcome: Vascular deaths plus ischaemic events" data-id="CD009893-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: Efficacy outcome: Vascular deaths plus ischaemic events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: Safety outcome: Fatal and non‐fatal haemorrhages" data-id="CD009893-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: Safety outcome: Fatal and non‐fatal haemorrhages</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009893-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009893-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/full#CD009893-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy, Outcome 1 Vascular deaths and ischaemic events." data-id="CD009893-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Efficacy, Outcome 1 Vascular deaths and ischaemic events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Safety, Outcome 1 Fatal and non‐fatal haemorrhages." data-id="CD009893-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Safety, Outcome 1 Fatal and non‐fatal haemorrhages.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Efficacy: sensitivity analyses, Outcome 1 Vascular deaths and ischaemic events." data-id="CD009893-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Efficacy: sensitivity analyses, Outcome 1 Vascular deaths and ischaemic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety: sensitivity analyses, Outcome 1 Fatal and non‐fatal haemorrhages." data-id="CD009893-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Safety: sensitivity analyses, Outcome 1 Fatal and non‐fatal haemorrhages.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 1 Adverse events that lead to discontinuation of treatment." data-id="CD009893-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 1 Adverse events that lead to discontinuation of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse events, Outcome 2 Serious adverse events." data-id="CD009893-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Adverse events, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Hepatotoxicity, Outcome 1 ALT or AST &gt; 3x ULN." data-id="CD009893-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Hepatotoxicity, Outcome 1 ALT or AST &gt; 3x ULN.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009893-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/urn:x-wiley:14651858:media:CD009893:CD009893-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_t/tCD009893-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Overall mortality, Outcome 1 Death from all causes." data-id="CD009893-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Overall mortality, Outcome 1 Death from all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/media/CDSR/CD009893/image_n/nCD009893-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Vascular deaths and ischaemic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.06, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.83, 1.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Safety</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatal and non‐fatal haemorrhages <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.78, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.55, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Safety</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Efficacy: sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Vascular deaths and ischaemic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Excluding Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 All doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Excluding myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Dabigatran 110 mg bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Dabigatran 150 mg bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Efficacy: sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Safety: sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fatal and non‐fatal haemorrhages <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Excluding Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 All doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.78, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Dabigatran 110 mg bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Dabigatran 150 mg bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Safety: sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events that lead to discontinuation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.82, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.77, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.79, 12.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.09, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.12, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.57, 1.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Hepatotoxicity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ALT or AST &gt; 3x ULN <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.60, 3.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Hepatotoxicity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009893-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Overall mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death from all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dabigatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZD0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 8.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Overall mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009893.pub2/references#CD009893-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009893.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009893-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009893-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009893-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009893-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009893-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD009893-note-0003">한국어</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009893-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009893\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009893\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009893\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009893\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009893.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009893.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009893.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009893.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009893.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713907704"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009893.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713907708"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009893.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d61b6092e937a',t:'MTc0MDcxMzkwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 